Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Oxford University Hospitals NHS Trust
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed NSCLC except bronchoalveolar cancer
Patients deemed suitable for radical RT according to local policy
TNM stage T1-2, N0-1, M0 plus patients with local recurrence
Adequate lung function as defined by protocol
Age ≥ 18 years
ECOG performance status 0-2
Written informed consent
Patient able and willing to comply with all protocol requirements
You may not be if
History of other active invasive malignancy (excluding non-melanoma skin cancer and in situ carcinoma of the cervix), where the extent of disease or treatment for that condition may interfere with the study endpoints
Previous RT to the chest
Chemotherapy, immunotherapies or investigational medicinal products within 4 weeks of the start of nelfinavir treatment. Ie any neoadjuvant treatment must be completed 4 weeks prior.
Liver impairment (serum bilirubin ≥ 2 times upper limit of normal, serum AST ≥ 2 times the upper limit of normal)
Pregnant or breast-feeding women or women of childbearing potential unless effective methods of contraception are used. Contraceptives that contain norethisterone or ethinylestradiol must be replaced by other contraceptive measures
Concurrent use of contraindicated drugs that cannot be substituted or discontinued 2 weeks or more prior to the start of trial treatment
Known hypersensitivity to nelfinavir or any of its excipients
Other psychological, social or medical condition, physical examination finding or a laboratory abnormality that the Investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results
Clareo Health | Radical Lung Radiotherapy Plus Nelfinavir
